Immune Response to the Human Papillomavirus Vaccine in Young Women With Inflammatory Bowel Disease

Mayo Clinic logo

Mayo Clinic

Status and phase

Completed
Phase 4

Conditions

Inflammatory Bowel Disease
Uterine Cervical Dysplasia

Treatments

Biological: Human Papillomavirus Vaccine

Study type

Interventional

Funder types

Other
Industry

Identifiers

NCT01034358
09-000485

Details and patient eligibility

About

The Gardasil vaccine, a vaccine targeted towards the human papillomavirus (HPV), has been shown to prevent the transmission of several strains of HPV in young women. Women with inflammatory bowel disease (IBD) may not respond as well to this vaccine, either due to having IBD or due to immunosuppressants used to control IBD. This study will test how well women with IBD respond to the Gardasil vaccine.

Full description

Although guidelines exist for immunization of patients with inflammatory bowel disease, few studies exist demonstrating vaccine efficacy in this population. In patients with inflammatory bowel disease, lower than normal humoral responses have been shown with the tetanus toxoid booster, oral cholera, and influenza vaccinations. It is currently uncertain whether women with inflammatory bowel disease (IBD) have an increased risk of cervical dysplasia and cancer. Gardasil, a vaccine against human papilloma viruses (HPV) 6, 11, 16, and 18, has been approved for the prevention of cervical dysplasias and cancers in women ages 9-26 years. However, its immune response in immunocompromised or immunosuppressed patients is unknown. Young women with inflammatory bowel disease who have not received the HPV vaccine will receive the vaccine. The vaccine is given in 3 doses over 6 months. Response to the vaccine will be measured 6 months after completing the vaccine series.

Enrollment

15 patients

Sex

Female

Ages

9 to 26 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Women 9-26 years of age
  • Have inflammatory bowel disease (ie. Crohns disease or ulcerative colitis)

Exclusion criteria

  • Pregnancy
  • Taking corticosteroids
  • Allergy to yeast aluminum component of the HPV vaccine
  • Positive for all HPV types in the Gardasil vaccine-6, 11, 16, 18

Trial design

Primary purpose

Prevention

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

15 participants in 1 patient group

Human Papillomavirus Vaccine
Experimental group
Description:
The Gardasil HPV vaccine was administered in 3 doses: baseline, 2 months, and 6 months.
Treatment:
Biological: Human Papillomavirus Vaccine

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems